scholarly journals MiRNAs in Cervical Cancer Radio- and Chemotherapy Response

10.5772/68010 ◽  
2017 ◽  
Author(s):  
Jesús Adrián López ◽  
Angelica Judith Granados López
Keyword(s):  
Cervical Cancer ◽  
Chemotherapy Response

Squamous cell carcinoma antigen: prognostic significance and role in the monitoring of neoadjuvant chemotherapy response in cervical cancer.

1994 ◽  
Vol 12 (11) ◽  
pp. 2309-2316 ◽  
Author(s):  
G Scambia ◽  
P Benedetti Panici ◽  
E Foti ◽  
M Amoroso ◽  
G Salerno ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Neoadjuvant Chemotherapy ◽  
Squamous Cell ◽  
Locally Advanced ◽  
Chemotherapy Response ◽  
Advanced Cervical Cancer ◽  
Squamous Cell Carcinoma Antigen ◽  
Locally Advanced Cervical Cancer ◽  
Response To Neoadjuvant Chemotherapy

PURPOSE The aim of the study was to investigate the role of squamous cell carcinoma antigen (SCC) in the management of patients with locally advanced cervical cancer treated by neoadjuvant chemotherapy and radical surgery. PATIENTS AND METHODS SCC assay was performed with a radioimmunoassay kit in a series of 102 patients with locally advanced cervical cancer. The values of 2.5, 5, and 7 ng/mL were used to define SCC antigen positivity. The chi 2 and Fisher's exact test and the stepwise logistic regression were used to evaluate the distribution of marker values. Analysis of survival was performed using the Kaplan and Meier test and Cox multivariate regression analysis. RESULTS SCC levels were elevated in 65%, 45%, and 32% of patients with primary tumors for cutoff values of 2.5, 5, and 7 ng/mL, respectively. SCC pretreatment levels correlated with stage, tumor volume and lymph node status. In the multivariate analysis, SCC expression proved to be an independent predictor of response to neoadjuvant chemotherapy. SCC posttreatment levels were strongly related to chemotherapy response. Moreover, the overall correlation between the clinical course of the disease and the variation of SCC levels was 83%. In patients with squamous cell tumors, survival was significantly longer in SCC-negative cases compared with SCC-positive cases (P = .04). Moreover, in patients undergoing surgery after response to neoadjuvant chemotherapy, low SCC values were associated with better prognosis (P = .02). In the multivariate analysis, parametrial involvement and SCC status proved to retain an independent prognostic value. CONCLUSION Our data show that SCC assay may provide useful information to improve the prognostic characterization and disease monitoring of patients with locally advanced cervical cancer undergoing neoadjuvant chemotherapy.

scholarly journals Relationships between Histopathology Type and Neoadjuvant Chemotherapy Response for Cervical Cancer Stage IB2 and IIA2

2020 ◽  
Vol 8 (B) ◽  
pp. 507-513
Author(s):  
Syamel Muhammad ◽  
Jamsari Jamsari ◽  
Netti Suharti ◽  
Yudi Mulyana Hidayat ◽  
Gistin Husnul Khatimah
Keyword(s):  
Cervical Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Chemotherapy Resistance ◽  
Transrectal Ultrasound ◽  
Evaluation Criteria ◽  
Complete Response ◽  
Chemotherapy Response ◽  
Cancer Stage ◽  
Therapy Strategy ◽  
Definitive Therapy

BACKGROUND: Cervical cancer was the fourth common women cancer in the world and the second most in Indonesia. Chemotherapy has been evaluated as a therapy strategy to treat cervical cancer stage IB2 and IIA2 prior the radical hysterectomy. Neoadjuvant chemotherapy was still being a controversy for the chemotherapy resistance patient and will delay the definitive therapy. A marker is needed to identify patient which more relatively resistant to chemotherapy. Squamous cell carcinoma (SCC) type was known to have a better response to neoadjuvant chemotherapy than non-SCC (nSCC) type, but they are no studies at Dr. M. Djamil Padang General Hospital yet on this matter before. OBJECTIVE: The objectives of the study were to obtain the relationship between histopathology type and neoadjuvant chemotherapy response for cervical cancer stage IB2 and IIA2. METHODS: This cohort analytic study conducted at Dr. M Djamil Padang Hospital which obtained 35 samples of stage IB2 and IIA2 cervical cancer patients whom treated with neoadjuvant chemotherapy. Results of histopathology are based on biopsy at diagnosis done for cervical cancer and chemotherapy response is based on transrectal ultrasound examinations before and after given neoadjuvant chemotherapy with response evaluation criteria in solid tumors criteria. RESULTS: Complete response and partial response in the SCC and nSCC group were 32%–50%, while stable disease (SD) and progressive disease were 68% in the SCC group to 50% in the nSCC group. CONCLUSION: There was no significant relationship between histopathological type and neoadjuvant chemotherapy response for cervical cancer stage IB2 and IIA2 (p = 0.44).

scholarly journals Vascular Endothelial Growth Factor-C (VEGF-C) Expression Can Not Predict Pelvic Lymph Node Metastases and Response to Neo-adjuvant Chemotherapy in Bulky Cervical Cancer

2016 ◽  
Author(s):  
Johnson Hutapea
Keyword(s):  
Cervical Cancer ◽  
Multivariate Analysis ◽  
Neoadjuvant Chemotherapy ◽  
Tumour Size ◽  
Response To Treatment ◽  
Chemotherapy Response ◽  
Response To Chemotherapy ◽  
The Difference ◽  
Neo Adjuvant Chemotherapy ◽  
Factor C

Objective: To assess whether VEGF-C expression can predict the response to neoadjuvant chemotherapy and pelvic lymphnode metastases in bulky cevical cancer. Methods: Seventeen cervical cancer stage IB2 and IIA2 cases during the period of July 2009 until June 2010 were collected consecutively and given neoadjuvant chemotherapy (NAC) PVB prior radical surgery. Response to treatment was evaluated based on the change of tumour size. VEGF-C expression was examined immunohistochemically at tumour biopsy before chemotherapy. The presence of lymphnode metastases histopathologically were obtained from pelvic lymphnode dissection. The difference and correlation of response and metastases on VEGF-C expression were analized statistically. The validity of the cut off percentage of immunopositive cells to VEGF-C to identify non responding and metastatic cases was calculated with the ROC. Multivariate analysis were done to determine the predictor of no response to chemotherapy. Results: Clinical response, using the RECIST version 1.1 criteria, was found in 41.18% cases and lymphnode metastases were found in 27.27% cases. VEGF-C was expressed in all cases. Statistically, there were no significant differences and correlation in response to treatment and pelvic lymphnode metastases on VEGF-C expression. At the cut off ≥ 76% immunopositivity to VEGF-C, the sensitivity to identify no response and the specificity to identify response to NAC are 70.00% and 71.43% respectively (LR+ 2.45 and LR- 0.42); whereas at the cut off ≥ 75% immunopositivity to VEGF-C, the sensitivity to identify lymphnode metastases and the specificity to identify no lymphnode metastases are 100.00% and 75.00% (LR+ 4.0 and LR- 0). With multivariate analysis using logistic regression, the cut off ≥ 76% immunopositive cells to VEGF-C were found to have positive coefficient, largest OR and statistic score, 1.93, 6.88 (96% CI OR 0.45; 104.34) and 41 respectively, to predict non responders in a prediction score model. Conclusion: VEGF-C expression on biopsy specimen bulky cervical cancers can not differentiate cases that respond to NAC and metastases to the pelvic lymphnode from that do not. The cut off ≥ 76% immunopositive cells to VEGF-C in a prediction model can be used as an alternative predictor to identify non responders. [Indones J Obstet Gynecol 2012; 36-3: 144-9] Keywords: bulky cervical cancer, neoadjuvant chemotherapy, response and metastases prediction, VEGF-C immunohistochemistry expression

scholarly journals Caspase-3 can not be Used to Predict the Response to Neoadjuvant Chemotherapy Regiment PVB in Cervical Cancer Stage IB-IIA

2016 ◽  
pp. 156-160
Author(s):  
Ediwibowo Ambari ◽  
Hariyono Winarto ◽  
Bambang Sutrisna ◽  
Budiningsih Siregar
Keyword(s):  
Cervical Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Caspase 3 ◽  
Early Stage ◽  
Response To Therapy ◽  
Bivariate Analysis ◽  
Chemotherapy Response ◽  
Cancer Stage ◽  
Significant Difference ◽  
Early Stage Cervical Cancer

Objectives: To determine the factors that may be used as the prognostic parameter for the therapeutic efficacy of neoadjuvant chemotherapy, which can be used to revising the management of early stage cervical cancer patients with large lesions. Methods: This was a retrospective cohort study. The study was conducted in the Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, University of Indonesia. The subjects were 15 cervical cancer stage IB2 and IIA patients with lesions’ size of > 4 cm, who would be treated with neoadjuvant chemotherapy, consisted of cisplatin 50 mg/m2, vincristine 2 mg/m2 and bleomycin 15 mg regiment. The patients’ response would be evaluated after completing 3 series of chemotherapy. Data was retrieved from medical records and cervical biopsy paraffin blocks and examined histopathologically using IHC staining to see expression of caspase-3 with histoscore assessment score. Data was analyzed by univariate, bivariate analysis. Results: Response to PVB neoadjuvant chemotherapy was found in 5 out of 15 patients. None of the clinicopathology variables can be used to predict response to therapy. Expression of caspase-3 as a marker of apoptosis, can not predict the response of the therapy before administrating neoadjuvant chemotherapy either. There is a significant difference between the levels of caspase-3 in epidermoid carcinoma with adenocarcinoma, with p value of 0.02 (RR 6;95% CI 1.69-21.26). Conclusion: Clinicopathologic factors and the expression of caspase-3 before getting chemotherapy neoadjuvant can not predict the succeed of the therapy. [Indones J Obstet Gynecol 2013; 1-3: 156-60] Keywords: caspase -3, clinicopathologic, early-stage cervical cancer lession in large, neoadjuvant chemotherapy response to therapy

scholarly journals Predictive role of galectin-1 and integrin α5β1 in cisplatin-based neoadjuvant chemotherapy of bulky squamous cervical cancer

2017 ◽  
Vol 37 (5) ◽  
Author(s):  
Haiyan Zhu ◽  
Aixue Chen ◽  
Saisai Li ◽  
Xuejiao Tao ◽  
Bo Sheng ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Rna Sequencing ◽  
Stromal Cells ◽  
Chemotherapy Response ◽  
Sequencing Data ◽  
Integrin Α5β1 ◽  
Squamous Cervical Cancer

Although galectin-1 and integrin α5β1 confer chemoresistance to certain types of cancer, whether their expression predicts the response to cisplatin-based neoadjuvant chemotherapy (NACT) in squamous cervical cancer remains unclear. Paired tumor samples (pre- and post-chemotherapy) were obtained from 35 bulky squamous cervical cancer patients treated with cisplatin-based NACT and radical hysterectomy at our hospital between January 2007 and August 2014. The expression of galectin-1 and integrin α5β1 in tumor cells and stromal cells was analyzed by immunohistochemistry. The correlation between galectin-1/integrin α5β1 and apoptosis-associated markers was investigated by using the The Cancer Genome Atlas (TCGA) RNA-sequencing data. Seventeen patients were identified as chemotherapy responders and 18 as non-responders. Galectin-1 and integrin α5β1-positive immunostaining was more frequently observed in stromal cells than its in tumor cells. The expression of galectin-1 and integrin α5β1 in stromal and tumor cells was significantly down-regulated in postchemotherapy cervical cancer tissues. High levels of galectin-1 and integrin α5β1 in stromal were associated with a negative chemotherapy response in squamous cervical cancer patients treated with cisplatin-based NACT. Additionally, the expression of galectin-1 and integrin α5 correlated negatively with caspase 3/caspase 8 by using the TCGA RNA-sequencing data. Galectin-1 and integrin α5β1 expression in stromal may serve as a prediction of the responses to cisplatin-based NACT for patients with bulky squamous cervical cancer. Galectin-1 and integrin α5β1 may be implicated in the development of chemoresistance in cervical cancer via suppressing apoptosis.

Multiple tumour marker assays in advanced cervical cancer: Relationship to chemotherapy response and clinical outcome

1996 ◽  
Vol 32 (2) ◽  
pp. 259-263 ◽  
Author(s):  
G. Scambia ◽  
P.Benedetti Panici ◽  
E. Foti ◽  
G. Ferrandina ◽  
F.P.G. Leone ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Clinical Outcome ◽  
Tumour Marker ◽  
Chemotherapy Response ◽  
Advanced Cervical Cancer ◽  
Multiple Tumour
Sign in / Sign up

Export Citation Format

Share Document